전이성 신세포암의 치료에서 전이병소 절제술 및 면역화학요법을 이용한 복합요법의 의의
The Role of Metastasectomy and Immunochemotherapy in Multimodal Therapy for Metastatic Renal Cell Carcinoma
전상원, 전승현, 장성구,
소속 상세정보
전상원 ( Chon Sang-Wohn )
경희대학교 의과대학 비뇨기과학교실
전승현 ( Jeon Seung-Hyun )
경희대학교 의과대학 비뇨기과학교실
장성구 ( Chang Sung-Goo )
경희대학교 의과대학 비뇨기과학교실
KMID : 0358320080490010001
Abstract
Purpose: One third of renal cell caricinoma(RCC) patients present with metastatic disease and 20-40% of these patients who undergo nephrectomy for clinically localized RCC will develop metastases. Eventually, the number of those patients who develop metastatic disease will increase to 30- 50%. The aim of this study is to compare the efficacy and survival rate in relation to the time of performing metastasectomy and immnuochemotherapy.
Materials and Methods: We retrospectively enrolled 12 patients who had undergone radical nephrectomy, immunochemotherapy and metastasectomy between 1998 and 2007. The patients were subdivided into two groups. Group 1 included the patients who received radical nephrectomy, metastasectomy and immunochemotherapy altogether. Group 2 included the patients who developed metachronous metastases during follow-up after radical nephrectomy and so they then underwent metastasectomy and immunochemotherapy. We compared the survival rates between the two groups.
Results: The sites of initial metastasis were found to be 8 cases of lung metastasis, 2 of bone metastasis, 1 of brain metastasis and 1 of colon metastasis. The 5-year survival rate of the 5 patients from group 1 was 37.5%. In group 2, the 5-year survival rate of the 7 patients was 71.4% and the disease-free mean interval between primary resection of the kidney and metastasectomy was 36.43±7.62 months. Statistically, there was no significant difference of survival rates between the two groups.
Conclusions: The results of this study suggest that metastasectomy followed by radical nephrectomy results in a longer survival time for the patients with metastatic cancer than that of patient that undergo radical nephretomy, metastasectomy and immunotherapy at the same time. We can recommend metastasetomy any time for the RCC patients who have technical resectable metastases with possibly positive prognostic factors and a good functional condition.
키워드
Renal cell carcinoma;Metastasis;Immunotherapy
원문 및 링크아웃 정보
등재저널 정보